Bayer

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News 2013

The news contents can be obtained from our website www.investor.bayer.com

Date	News
December 19, 2013	Not intended for U.S. and UK Media **Bayer plans to acquire Norwegian pharmaceutical company Algeta** - Successful collaboration on cancer medicine Xofigo™ - Transaction would give Bayer full control over Xofigo™ - Public takeover offer planned at a price of NOK 362 per Algeta share in cash - Offer unanimously recommended by Algeta's Board of Directors - Pre-acceptance for approximately 14 % of the shares
December 18, 2013	**Kemal Malik appointed Bayer AG Board of Management member with responsibility for Innovation** Professor Wolfgang Plischke to retire on April 30, 2014
December 12, 2013	**Bayer Investor Relations Website Relaunched**
November 28, 2013	Not intended for U.S. and UK Media - Myopic Choroidal Neovascularization: **Bayer Submits VEGF Trap-Eye (aflibercept solution for injection) for the Treatment of Myopic Choroidal Neovascularization in Japan**
November 22, 2013	Not intended for U.S. and UK Media **Nexavar® Receives Approval for the Treatment of Differentiated Thyroid Cancer in the U.S.** - First and only FDA-approved treatment option for patients with this type of thyroid cancer - FDA approval based on data from Phase III DECISION trial, in which sorafenib significantly extended progression-free survival compared to placebo
November 22, 2013	Not intended for U.S. and UK Media **Bayer Receives Approval for EYLEA® in Japan for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion**
November 15, 2013	Not intended for U.S. and UK Media **Bayer Receives Approval for New Cancer Drug Xofigo® in the EU** - New treatment for adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases - Xofigo significantly extended overall survival in Phase III ALSYMPCA study
November 11, 2013	Not intended for U.S. and UK Media **Portola Pharmaceuticals Announces Initial Phase II Results Demonstrating Dose-Dependent Reversal of Bayer's Xarelto® Anticoagulation Activity with Andexanet Alfa (PRT4445)** Data set with additional dosing cohorts to be presented at 55th American Society of Hematology (ASH) Annual Meeting and Exposition
November 07, 2013	Not intended for U.S. and UK Media **Bayer Submits VEGF Trap-Eye (aflibercept solution for injection) for Treatment of Diabetic Macular Edema in the EU**

October 31, 2013 — Third quarter of 2013:
Bayer continues positive business momentum
- Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter
- New pharmaceutical products post excellent growth
- Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent)
- EBIT shows 47.5 percent improvement to EUR 1,221 million
- EBITDA before special items moves 7.7 percent higher to EUR 1,984 million
- Net income advances by 42.1 percent to EUR 733 million
- Core earnings per share up 8.5 percent to EUR 1.27
- Group guidance for 2013 maintained

October 09, 2013 — Not intended for U.S. and UK Media
U.S. FDA Approves Bayer's Adempas® (riociguat), the first soluble Guanylate Cyclase Stimulator, in Two Forms of Pulmonary Hypertension
- Adempas is now available in the U.S. as the first and only drug approved to treat chronic thromboembolic pulmonary hypertension (CTEPH)
- Adempas also received approval in Pulmonary Arterial Hypertension (PAH)
- Adempas has been developed to target a key molecular mechanism underlying this serious disorder of the heart and lungs

October 08, 2013 — Not intended for U.S. and UK Media
Bayer Accelerates Clinical Development of Promising New Drug Candidates
- Five new molecular entities projected to enter Phase III by 2015
- Addressing unmet medical needs in the areas of oncology, cardiology, and women's health
- Initiation of further studies with recently launched products planned to add new treatment options

September 30, 2013 — Not intended for U.S. and UK Media
Bayer Submits Nexavar® (Sorafenib) for Marketing Authorization in Thyroid Cancer in Japan
- Regulatory submission based on positive data from Phase III DECISION trial, in which sorafenib significantly extended progression-free survival
- Sorafenib has been granted orphan drug status for the treatment of patients with thyroid cancer in Japan

September 30, 2013 — **Olivier Brandicourt appointed as new CEO of Bayer HealthCare**

September 20, 2013 — Not intended for U.S. and UK Media
Bayer Receives Recommendation for Approval of Radium Ra 223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer with Bone Metastases in the European Union

September 05, 2013 — Increasing demand for innovative and sustainable agricultural solutions
Bayer CropScience steps up investment plans: EUR 2.4 billion earmarked for capacity expansion between 2013 and 2016
- Production of key active ingredients to increase substantially
- On track to grow sales towards EUR 10 billion in 2015

September 05, 2013 — Not intended for U.S. and UK Media
Bayer's Regorafenib Submitted for European Marketing Authorization for the Treatment of Gastrointestinal Stromal Tumors (GIST)
EMA filing follows EU approval of Stivarga® (regorafenib) for use in metastatic colorectal cancer

August 30, 2013 — Not intended for U.S. and UK Media
Bayer's Stivarga® (regorafenib) Approved in the EU for the Treatment of Metastatic Colorectal Cancer

August 29, 2013 — Not intended for U.S. and UK Media
Bayer Receives Approval for EYLEA® in Next Indication in Europe
Approval for the treatment of visual impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (CRVO) marks second indication for EYLEA

August 27, 2013	Not intended for U.S. and UK Media **Nexavar® (sorafenib) Granted Priority Review for Differentiated Thyroid Cancer in the U.S.** Currently no approved therapies specifically for differentiated thyroid cancer refractory to radioactive iodine
August 20, 2013	Not intended for U.S. and UK Media **Bayer's Stivarga® Approved for the Treatment of Patients with Gastrointestinal Stromal Tumors in Japan**
August 06, 2013	Not intended for U.S. and UK Media - Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension: **U.S. FDA Advisory Committee Unanimously Recommends Approval of Bayer's Riociguat in Two Forms of Pulmonary Hypertension**
August 06, 2013	Not intended for U.S. and UK Media **VEGF Trap-Eye (aflibercept solution for injection) Met Primary Endpoint in Two Phase 3 Trials for the Treatment of Diabetic Macular Edema**
July 31, 2013	Second quarter of 2013: **Bayer: strong growth in Life Sciences** - HealthCare and CropScience post dynamic growth, MaterialScience weak - New pharmaceutical products well above expectations - Group sales rise 1.9 percent (Fx & portfolio adj. 4.6 percent) to EUR 10,360 million - EBIT advances by 73.9 percent to EUR 1,287 million - EBITDA before special items up by 1.2 percent to EUR 2,195 million - Net income climbs 74.8 percent to EUR 841 million - Core earnings per share up 6.2 percent to EUR 1.54 - Group outlook for 2013 maintained
July 26, 2013	Not intended for U.S. and UK Media **Bayer Receives Recommendation for Approval of VEGF Trap-Eye (aflibercept solution for injection) for the Treatment of Visual Impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe**
July 01, 2013	**Bayer completes acquisition of Steigerwald** Christian Sarto appointed Managing Director
July 01, 2013	Not intended for U.S. and UK Media **Sorafenib (Nexavar®) Submitted to the EMA and FDA for the Treatment of Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer** - Currently no approved therapies specifically for differentiated thyroid cancer refractory to radioactive iodine - Regulatory submissions based on data from Phase III DECISION trial, in which sorafenib significantly extended progression-free survival compared to placebo
June 28, 2013	Not intended for U.S. and UK Media **U.S. FDA Issues Complete Response Letter for Bayer's Xarelto® to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome**
June 28, 2013	Not intended for U.S. and UK Media **Bayer's Regorafenib Recommended for Approval in the European Union for the Treatment of Metastatic Colorectal Cancer** Regorafenib shown in a pivotal Phase III trial to extend overall survival in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after previous treatments
June 06, 2013	Not intended for U.S. and UK Media - VEGF Trap-Eye in myopic choroidal neovascularization: **Positive Phase 3 Results for VEGF Trap-Eye (Intravitreal Aflibercept) in Myopic Choroidal Neovascularization (mCNV)**
June 05, 2013	Tender offer successful: **Bayer acquires majority interest in Conceptus** - 96.4 percent of Conceptus' shares tendered - Conceptus imminently to become a wholly-owned Bayer subsidiary

June 02, 2103	Not intended for U.S. and UK Media - Results of pivotal Phase III study in differentiated thyroid cancer: **Positive Phase III Data on Sorafenib Show Significant Improvement in Progression-Free Survival Time in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer** - Currently there are no approved therapies specifically for radioactive iodine refractory differentiated thyroid cancer - Sorafenib (Nexavar®) significantly extended progression-free survival; median progression-free survival of 10.8 months, compared to 5.8 months with placebo - Results from pivotal Phase III DECISION trial presented in plenary session at Annual Meeting of the American Society of Clinical Oncology
May 24, 2013	Not intended for U.S. and UK Media **Bayer's Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome** - Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year - Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone - Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant
May 20, 2013	Not intended for U.S. and UK Media - American Thoracic Society International Conference, Philadelphia, USA: **Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat** - Riociguat showed good long-term safety profile (1) - Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH) (1)
May 17, 2013	Not intended for U.S. and UK Media **Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan**
May 16, 2013	Strategic move to strengthen Consumer Care business: **Bayer to acquire Steigerwald Arzneimittelwerk GmbH** Transaction includes Iberogast® and Laif® brands
May 16, 2013	Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO): **Bayer to Present New Data Across Oncology Portfolio at ASCO 2013** - First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session - Data presentations for three oncology products across five tumor types
May 15, 2013	Not intended for U.S. and UK Media **Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection** - New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases - Xofigo shown in a pivotal Phase III trial to significantly improve overall survival
May 15, 2013	Not intended for U.S. and UK Media **Bayer Initiates Phase III Trial of Regorafenib in Patients with Advanced Liver Cancer**

May 08, 2013	Not intended for U.S. and UK Media - The American Thoracic Society International Conference 2013: **Bayer to Present Data on Pulmonary Hypertension Research at the ATS International Conference 2013 in Philadelphia** - Interim Analysis from Long-Term Extension Study PATENT-2 Phase III - Hemodynamic data and clinical correlation from CHEST-1 Phase III - New Data Sets from Pivotal PATENT-1 Phase III
May 07, 2013	Not intended for UK Media **Bayer commences cash tender offer for all outstanding shares of Conceptus, Inc.**
May 03, 2013	Not intended for UK Media **Bayer Provides Update on Phase II/III Trial of BAY 86-6150**
April 29, 2013	Not intended for UK media - Strategic expansion of Women's Health business: **Bayer to acquire Conceptus, Inc.** Adds Essure®, the only non-surgical permanent birth control method, to Bayer's contraception portfolio
April 26, 2013	Dr. Marijn Dekkers at the Annual Stockholders' Meeting of Bayer AG: **"Bayer is a world-class innovation company"** - 2012 operationally a very successful year - Highest sales in the company's 150-year history - Proposal to raise dividend for 2012 to EUR 1.90 per share - Employees to benefit from the company's success with bonuses totaling over EUR 700 million - Life Sciences off to a good start in anniversary year
April 25, 2013	First quarter of 2013: **Bayer: Life Sciences off to a good start in anniversary year** - New pharmaceutical products spur growth at HealthCare, continuing strong development at CropScience, cost pressure at MaterialScience - Group sales up 2.1 percent to EUR 10,266 million - EBIT improves by 8.6 percent to EUR 1,771 million - EBITDA before special items increased by 0.4 percent to EUR 2,453 million - Net income rises 11.5 percent to EUR 1,160 million - Gratifying development in Emerging Markets - Group outlook for 2013 confirmed
April 16, 2013	**Bayer CropScience and Monsanto Enter into Cross-Licensing Agreements for Next-Generation and Enabling Technologies** - Agreements Create More Options for Farmers - Expanded Market Opportunities for Next-Generation Technologies
April 16, 2013	Not intended for U.S. and UK Media **First Patient Enrolled in Global Phase III Program Evaluating Bayer's Amikacin Inhale in Intubated and Mechanically Ventilated Patients with Gram-negative Pneumonia** Treatments to complement current standard of care urgently needed as morbidity and mortality is significant in this patient population
April 08, 2013	Not intended for U.S. and UK Media **U. S. FDA Grants Priority Review to Bayer's Riociguat for the Treatment of two Life-Threatening Pulmonary Hypertension Indications**
March 28, 2013	**Bayer CropScience and Syngenta propose a comprehensive action plan to help unlock EU stalemate on bee health**
March 25, 2013	Not intended for U.S. and UK Media **Bayer's Stivarga® (regorafenib) Tablets Approved in Japan for the Treatment of Advanced or Recurrent Colorectal Cancer**

March 22, 2013 — Not intended for U.S. and UK Media - Acute Coronary Syndrome (ACS)
Bayer's Xarelto® (Rivaroxaban) Recommended for Approval in the EU for the Prevention of Atherothrombotic Events after an ACS
- Xarelto 2.5 mg twice-daily (BID) demonstrated significant clinical benefit for patients with ACS when used with standard antiplatelet therapy
- Complementary modes of action of Xarelto 2.5 mg BID and antiplatelet therapy have the potential to provide more complete protection against long-term clot formation
- Final decision from the European Commission expected in the first half of 2013

March 08, 2012 — Not intended for U.S. and UK Media
Bayer Initiates Xarelto® (Rivaroxaban) Study in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention with Stent Placement

March 08, 2013 — Not intended for U.S. and UK Media
New Pivotal Phase III Study Initiated with Bayer's Xarelto® (Rivaroxaban) in Patients with Chronic Heart Failure and Significant Coronary Artery Disease
Low-dose rivaroxaban given fast track designation by U.S. FDA as first novel oral anticoagulant to be evaluated in this high-risk patient group

March 05, 2013 — Not intended for U.S. and UK Media: Acute Coronary Syndrome (ACS):
U.S. FDA Issues Complete Response Letter for Bayer's Xarelto® (Rivaroxaban) for the Reduction of Cardiovascular Events in Patients with ACS

March 04, 2013 — Not intended for U.S. and UK Media - Long-term extension study of Riociguat in patients with CTEPH:
Interim results from CHEST-2 study support benefits of Bayer's Riociguat as demonstrated in Phase III CHEST-1 study
- Riociguat showed significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with inoperable or residual chronic thromboembolic pulmonary hypertension (CTEPH) (1)
- Riociguat showed good long-term safety profile (1)

February 28, 2013 — New products create optimism for the future
Bayer: continuing growth momentum
- Group targets achieved in 2012 - sales and earnings before special items increase in all subgroups
- Sales increase by 8.8 percent to EUR 39,760 million
- EBIT EUR 3,960 million (minus 4.6 percent) - Net income EUR 2,446 million (minus 1.0 percent)
- Further accounting measures for legal claims
- EBITDA before special items rises by 8.8 percent to EUR 8,284 million
- Core earnings per share improve by 10.8 percent to EUR 5.35
- Encouraging growth in the emerging markets
- Steady progress with innovation pipeline strengthens life-science businesses
- Forecast for anniversary year 2013: continuing record development

February 26, 2013 — **Bayer proposes dividend increase to EUR 1.90 per share for 2012**
Payout up 15 percent to EUR 1,571 million

February 26, 2013 — Not Intended for U.S. and U.K. Media
Bayer's Regorafenib Granted Priority Review in Japan for the Treatment of Patients with Gastrointestinal Stromal Tumors

February 25, 2013 — Not intended for U.S. and UK media
Bayer's Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Gastrointestinal Stromal Tumors
Stivarga shown in a pivotal Phase III trial to significantly improve progression-free survival in patients with gastrointestinal stromal tumors (GIST) whose disease had progressed after previous treatments

February 19, 2013 — Not intended for U.S. and UK Media
Bayer and Regeneron Initiate Phase III Trial of VEGF Trap-Eye (Aflibercept) for the Treatment of Diabetic Macular Edema in Asia and Russia

February 13, 2013	Not intended for U.S. and UK Media - Castration-Resistant Prostate Cancer with Bone Metastases: **Radium-223 Dichloride Granted Priority Review by U.S. FDA**
February 11, 2013	Not intended for U.S. and UK media **Bayer's Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension Submitted For Regulatory Approval in the U.S. and EU** Riociguat is the first drug that has consistently demonstrated efficacy in two life-threatening PH indications - chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
February 05, 2013	Not intended for U.S. and UK Media **Xarelto® to be Studied with Factor Xa Inhibitor Antidote** Bayer and Janssen announce clinical collaboration agreement with Portola
February 01, 2013	**Not intended for U.S. and UK media - IMCAS Congress 2013** Positive results of Phase-III trials suggest that ATX-101 is effective as a non-surgical treatment for the reduction of unwanted submental fat
January 23, 2013	**Dr. Jörg Reinhardt to leave Bayer HealthCare**
January 10, 2013	Not intended for U.S. and UK media **Bayer receives approval for new long-term contraceptive Skyla™ in the U.S.** - New low dose levonorgestrel-releasing intrauterine system (IUS) - Longterm contraception for up to three years
January 07, 2013	Not intended for U.S. and UK media **Bayer Submits VEGF Trap-Eye (aflibercept) for Treatment of Macular Edema** Following Central Retinal Vein Occlusion in Japan
January 04, 2013	Not intended for U.S. media **Bayer HealthCare completes acquisition of Teva's U.S. animal health business** New product lines strengthen Bayer's animal health business in the U.S.
January 03, 2013	Not intended for U.S. and UK media **Phase III DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer**